Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06575699 · ClinicalTrials.gov registry record · Phase 4
Rectus Sheath Block for Analgesia After Gynecological Laparotomy
A Phase 4 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT06575699 is a Phase 4 study that has completed, run by Duke University. The registered enrollment target is 90 participants.
The verdict
NCT06575699, a Phase 4 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
Thirty subjects undergoing laparotomy for Gynecologic oncology surgery will be prospectively enrolled and will receive a bilateral rectus sheath block (RSB) under ultrasound guidance using 133 mg liposomal bupivacaine and 20 ml bupivacaine 0.25% per side. Cases will be matched in a 1:2 ratio by age, race, insurance status and duration of surgery with historical controls who received postoperative analgesia using thoracic epidural analgesia.
Interventions
- DRUG Liposomal bupivacaine
- DRUG Bupivacaine Hydrochloride
- PROCEDURE Rectus sheath block
- PROCEDURE Thoracic Epidural Analgesia
- DRUG Bupivacaine-Hydromorphone Cassette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2025-11-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06575699
The ClinicalTrials.gov registry entry for NCT06575699 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Liposomal bupivacaine is the first listed.
NCT06575699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06575699 about?
NCT06575699 is a clinical study titled "Rectus Sheath Block for Analgesia After Gynecological Laparotomy". Thirty subjects undergoing laparotomy for Gynecologic oncology surgery will be prospectively enrolled and will receive a bilateral rectus sheath block (RSB) under ultrasound guidance using 133 mg liposomal bupivacaine and 20 ml bupivacaine 0.25% per side. Cases will be matched in a 1:2 ratio by age,...
What is the current status of trial NCT06575699?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2024-10-10. Estimated completion is 2025-11-28.
What interventions are being tested in trial NCT06575699?
The interventions under investigation include: Liposomal bupivacaine (DRUG), Bupivacaine Hydrochloride (DRUG), Rectus sheath block (PROCEDURE), Thoracic Epidural Analgesia (PROCEDURE), Bupivacaine-Hydromorphone Cassette (DRUG).
Who is sponsoring clinical trial NCT06575699?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.